Improved Epstein-Barr virus immunoglobulin M antibody test

Area of Science:

• Immunology
• Virology
• Medical Diagnostics

Background:

• Epstein-Barr virus (EBV) immunoglobulin M (IgM) antibody detection is crucial for diagnosing infectious mononucleosis.
• Previous methods for EBV IgM detection have faced challenges with reproducibility.
• Standardization of EBV IgM assays is needed for reliable clinical application.

Purpose of the Study:

• To develop a reproducible method for detecting Epstein-Barr virus immunoglobulin M (EBV IgM) antibodies in human sera.
• To optimize the existing three-coat immunofluorescence technique for EBV IgM testing.
• To assess the clinical utility and duration of EBV IgM antibodies in infectious mononucleosis cases.

Main Methods:

• Modified a three-coat immunofluorescence technique previously described by Schmitz and Scherer (1972).
• Utilized Hyland antihuman IgM antiserum, rendered specific by absorption on Cohn fraction II, in the second coat.
• Tested both fractionated and unfractionated human sera for EBV IgM antibodies.

Main Results:

• The specificity enhancement of the antihuman IgM antiserum was identified as the critical factor for reproducible EBV IgM results.
• EBV IgM antibodies were detected in 14 heterophil-positive infectious mononucleosis cases, appearing short-lived (≤2 months).
• EBV IgM antibodies were found in only 2 of 18 non-mononucleosis cases, both associated with EBV-viral capsid antigen antibody seroconversion.
• Nonspecific fluorescence was successfully eliminated through a simple, cost-effective procedure.

Conclusions:

• A modified, reproducible assay for EBV IgM antibodies has been established.
• The enhanced assay facilitates direct testing of unabsorbed, unfractionated sera, simplifying the diagnostic process.
• The short duration of EBV IgM antibodies suggests their utility as an early marker for acute EBV infection.